Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease
Patrick W.J.C. Serruys, Marie‐Claude Morice, A. Pieter Kappetein, Antonio Colombo, David R. Holmes, Michael J. Mack, Elisabeth Ståhle, Ted E Feldman, Marcel van den Brand, Eric J. Bass, Nic Van Dyck, Katrin Leadley, Keith D. Dawkins, Friedrich Wilhelm Mohr
New England Journal of Medicine · 2009 · 4,435 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Serruys, P. W., Morice, M., Kappetein, A. P., Colombo, A., Holmes, D. R., Mack, M. J., Ståhle, E., Feldman, T. E., Brand, M. van den, Bass, E. J., Dyck, N. V., Leadley, K., Dawkins, K. D., & Mohr, F. W. (2009). Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. New England Journal of Medicine, 360(10), 961–972. https://doi.org/10.1056/nejmoa0804626
In text: (Serruys et al., 2009)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: Percutaneous coronary intervention (PCI) involving drug-eluting stents is increasingly used to treat complex coronary artery disease, although coronary-artery bypass grafting (CABG) has been the treatment of choice historically. Our trial compared PCI and CABG for treating patients with previously untreated three-vessel or left main coronary artery disease (or both). METHODS: We randomly assigned 1800 patients with three-vessel or left main coronary artery disease to undergo CABG or PCI (in a 1:1 ratio). For all these patients, the local cardiac surgeon and interventional cardiologist determined that equivalent anatomical revascularization could be achieved with either treatment. A noninferiority comparison of the two groups was performed for the primary end point--a major adverse cardiac or cerebrovascular event (i.e., death from any cause, stroke, myocardial infarction, or repeat revascularization) during the 12-month period after randomization. Patients for whom only one of the two treatment options would be beneficial, because of anatomical features or clinical conditions, were entered into a parallel, nested CABG or PCI registry. RESULTS: Most of the preoperative characteristics were similar in the two groups. Rates of major adverse cardiac or cerebrovascular events at 12 months were significantly higher in the PCI group (17.8%, vs. 12.4% for CABG; P=0.002), in large part because of an increased rate of repeat revascularization (13.5% vs. 5.9%, P<0.001); as a result, the criterion for noninferiority was not met. At 12 months, the rates of death and myocardial infarction were similar between the two groups; stroke was significantly more likely to occur with CABG (2.2%, vs. 0.6% with PCI; P=0.003). CONCLUSIONS: CABG remains the standard of care for patients with three-vessel or left main coronary artery disease, since the use of CABG, as compared with PCI, resulted in lower rates of the combined end point of major adverse cardiac or cerebrovascular events at 1 year. (ClinicalTrials.gov number, NCT00114972.)
Related papers
- 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation2017
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes2019
- 2018 ESC/EACTS Guidelines on myocardial revascularization2018
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes2007
Metadata from OpenAlex (CC0). Citations are generated from the published record.